Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including OmicronSiling Wang, Ningshao Xia, Hai Yu et al.|Cell Reports|2022Cited by 36
Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitroHualong Xiong, Ningshao Xia|Frontiers in Pharmacology|2021Cited by 32
The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2Hualong Xiong, Ningshao Xia, Hui Sun et al.|Proceedings of the National Academy of Sciences|2022Cited by 28
A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding modeDongping Zhao, Haiming Huang, Liqin Liu et al.|Journal of Nanobiotechnology|2022Cited by 23